{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:54:22Z","timestamp":1788256462028,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2000,7,1]],"date-time":"2000-07-01T00:00:00Z","timestamp":962409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,7,1]],"date-time":"2000-07-01T00:00:00Z","timestamp":962409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2000,7]]},"DOI":"10.1023\/a:1006484604454","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T02:03:28Z","timestamp":1040522608000},"page":"1-17","source":"Crossref","is-referenced-by-count":52,"title":["Chemoprevention of breast cancer"],"prefix":"10.1007","volume":"62","author":[{"given":"Powel H.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"269875_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/canjclin.50.1.7","volume":"50","author":"RT Greenlee","year":"2000","unstructured":"Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7\u201333, 2000","journal-title":"CA Cancer J Clin"},{"key":"269875_CR2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al.: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371\u20131388, 1998","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR3","first-page":"253","volume":"20","author":"VC Jordan","year":"1999","unstructured":"Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253\u2013278, 1999","journal-title":"Endocr Rev"},{"key":"269875_CR4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1023\/A:1006348907994","volume":"17","author":"K Dhingra","year":"1999","unstructured":"Dhingra K: Antiestrogens\u2013tamoxifen, SERMs and beyond. Invest New Drugs 17: 285\u2013311, 1999","journal-title":"Invest New Drugs"},{"key":"269875_CR5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/jnci\/91.21.1809","volume":"91","author":"SM Lippman","year":"1999","unstructured":"Lippman SM, Brown PH: Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 91: 1809\u20131819, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group.","year":"1998","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451\u20131467, 1998","journal-title":"Lancet"},{"key":"269875_CR7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98\u2013101, 1998","journal-title":"Lancet"},{"key":"269875_CR8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(98)04394-3","volume":"352","author":"U Veronesi","year":"1998","unstructured":"Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352: 93\u201397, 1998","journal-title":"Lancet"},{"key":"269875_CR9","unstructured":"Wolmark N, Dignam J, Fisher B: The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): preliminary results of NSABP protocol B-24. Breast Cancer Res Treat 50: Abstract 1, 1998"},{"key":"269875_CR10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E et al.: Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 353: 1993\u20132000, 1999","journal-title":"Lancet"},{"key":"269875_CR11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/jnci\/90.20.1514","volume":"90","author":"SM Lippman","year":"1998","unstructured":"Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90: 1514\u20131528, 1998","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"CK Osborne","year":"1998","unstructured":"Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609\u20131618, 1998","journal-title":"N Engl J Med"},{"key":"269875_CR13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jnci\/90.13.967","volume":"90","author":"VC Jordan","year":"1998","unstructured":"Jordan VC: Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 90: 967\u2013971, 1998","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/jnci\/90.20.1552","volume":"90","author":"RM O'Regan","year":"1998","unstructured":"O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ et al.: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552\u20131558, 1998","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/91.2.188","volume":"91","author":"S Narod","year":"1999","unstructured":"Narod S: Letter: Re: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 91: 188, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852\u2013856, 1992","journal-title":"N Engl J Med"},{"key":"269875_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJM199702273360903","volume":"336","author":"Y Zhang","year":"1997","unstructured":"Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF et al.: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J. Med 336: 611\u2013616, 1997","journal-title":"N Engl J. Med"},{"key":"269875_CR18","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","volume":"17","author":"R Day","year":"1999","unstructured":"Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 17: 2659\u20132669, 1999","journal-title":"J Clin Oncol"},{"key":"269875_CR19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/jnci\/82.16.1327","volume":"82","author":"RR Love","year":"1990","unstructured":"Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP et al.: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82: 1327\u20131332, 1990","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR20","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","volume":"340","author":"ME Mendelsohn","year":"1999","unstructured":"Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular systesm. N Engl J Med 340: 1801\u20131811, 1999","journal-title":"N Engl J Med"},{"key":"269875_CR21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605\u2013613, 1998","journal-title":"JAMA"},{"key":"269875_CR22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.279.9.688","volume":"279","author":"K Yaffe","year":"1998","unstructured":"Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279: 688\u2013695, 1998","journal-title":"JAMA"},{"key":"269875_CR23","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jnci\/87.18.1372","volume":"87","author":"PA Ganz","year":"1995","unstructured":"Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B: Base-line quality of life assessment in the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial. J Natl Cancer Inst 87: 1372\u20131382, 1995","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR24","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.1999.17.6.1939","volume":"17","author":"RT Chlebowski","year":"1999","unstructured":"Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17: 1939\u20131955, 1999","journal-title":"J Clin Oncol"},{"key":"269875_CR25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","volume":"91","author":"MH Gail","year":"1999","unstructured":"Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829\u20131846, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/jnci\/88.21.1529","volume":"88","author":"B Fisher","year":"1996","unstructured":"Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529\u20131542, 1996","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR27","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1200\/JCO.1999.17.5.1632","volume":"5","author":"B Fisher","year":"1999","unstructured":"Fisher B: National surgical adjuvant breast and bowel project breast cancer prevention trial: a reflective commentary. J Clin Oncol 5: 1632\u20131639, 1999","journal-title":"J Clin Oncol"},{"key":"269875_CR28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jnci\/92.8.657a","volume":"92","author":"B Rockhill","year":"2000","unstructured":"Rockhill B, Colditz G, Kaye J: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 657\u2013658, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/92.8.658","volume":"92","author":"SM Lippman","year":"2000","unstructured":"Lippman SM, Brown PH: Response: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 658\u2013659, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jnci\/92.8.659","volume":"92","author":"B Fisher","year":"2000","unstructured":"Fisher B: Response: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 659\u2013660, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199901143400211","volume":"340","author":"K Phillips","year":"1999","unstructured":"Phillips K, Glendon G, Knight JA: Putting the risk of breast cancer in perspective. N Engl J Med 340: 141\u2013143, 1999","journal-title":"N Engl J Med"},{"key":"269875_CR32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM199905133401909","volume":"340","author":"DL Page","year":"1999","unstructured":"Page DL, Simpson JF: Ductal carcinoma in situ \u2014 The focus for prevention, screening, and breast conservation in breast cancer. N Engl J Med 340: 1499\u20131500, 1999","journal-title":"N Engl J Med"},{"key":"269875_CR33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/92.4.288","volume":"92","author":"ER Fisher","year":"2000","unstructured":"Fisher ER, Fisher B: Relation of a recurrent intraductal carcinoma (ductal carcinoma in situ) to the primary tumor. J Natl Cancer Inst 92: 288\u2013289, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR34","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(99)00194-4","volume":"12","author":"NR Wilcken","year":"1999","unstructured":"Wilcken NR: Tamoxifen hits the target in situ. Lancet 12: 353, 1986\u2013dy1987, 1999","journal-title":"Lancet"},{"key":"269875_CR35","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1200\/JCO.1999.17.9.2633","volume":"17","author":"A Decensi","year":"1999","unstructured":"Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B et al.: Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17: 2633\u20132683, 1999","journal-title":"J Clin Oncol"},{"key":"269875_CR36","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/jnci\/91.21.1792","volume":"91","author":"A. Taylor","year":"1999","unstructured":"Taylor Al, Adams-Campbell LL, Wright JT Jr: Risk\/benefit assessment of tamoxifen to prevent breast cancer \u2013 still a work in progress? [editorial]. J Natl Cancer Inst 91: 1792\u20131793, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR37","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/jnci\/92.7.574A","volume":"92","author":"AL Taylor","year":"2000","unstructured":"Taylor AL, Adams-Campbell LL, Wright JT Jr: Response: Re: Risk\/benefit assessment of tamoxifen to prevent breast cancer \u2013 still a work in progress? [letter]. J Natl Cancer Inst 92: 574\u2013575, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR38","first-page":"70a","volume":"19","author":"W McCaskill-Stevens","year":"2000","unstructured":"McCaskill-Stevens W, Bryant J, Costantino J, Wickerham DL, Vogel V, Wolmark N et al.: Incidence of contralateral breast cancer (CBC), endometrial cancer (EC), and thromboembolic events (TE) in African American (AA) women receiving tamoxifen for treatment of primary breast cancer [abstract]. Proc ASCO 19: 70a, 2000","journal-title":"Proc ASCO"},{"key":"269875_CR39","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(99)04336-6","volume":"354","author":"H Jernstrom","year":"1999","unstructured":"Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA: Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354: 1846\u20131850, 1999","journal-title":"Lancet"},{"key":"269875_CR40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Esaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475\u20131479, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W","volume":"83","author":"N Loman","year":"1998","unstructured":"Loman N, Johannsson O, Bendahl PA, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310\u2013319, 1998","journal-title":"Cancer"},{"key":"269875_CR42","first-page":"2011","volume":"59","author":"JE Armes","year":"1999","unstructured":"Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A et al.: Distinct molecular pathogeneses of earlyonset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011\u20132017, 1999","journal-title":"Cancer Res"},{"key":"269875_CR43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"J Hartmann","year":"1999","unstructured":"Hartmann J, Schaid D, Woods J, Crotty T, Myers J, Arnold P et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77\u201384, 1999","journal-title":"N Engl J Med"},{"key":"269875_CR44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199901143400209","volume":"340","author":"A Eisen","year":"1999","unstructured":"Eisen A, Weber BL: Prophylactic mastectomy \u2013 The price of fear. N Engl J Med 340: 137\u2013138, 1999","journal-title":"N Engl J Med"},{"key":"269875_CR45","first-page":"49","volume-title":"Contemporary Endocrinology: Endocrine Oncology","author":"P Brown","year":"2000","unstructured":"Brown P, Fuqua S, Allred C: Pathogenesis of estrogen receptor positive and negative breast cancer. In: Ethier SP, (ed). Contemporary Endocrinology: Endocrine Oncology. Totowa (NJ): Humana Press. p. 49\u201368, 2000"},{"key":"269875_CR46","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.284.5418.1354","volume":"284","author":"S Fan","year":"1999","unstructured":"Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR et al.: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354\u20131356, 1999","journal-title":"Science"},{"key":"269875_CR47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(98)24020-7","volume":"351","author":"P Osin","year":"1998","unstructured":"Osin P, Crook T, Powles T, Peto J, Gusterson B: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 351: 1487, 1998","journal-title":"Lancet"},{"key":"269875_CR48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/jnci\/92.2.92","volume":"92","author":"VC Jordan","year":"2000","unstructured":"Jordan VC: How is tamoxifen's action subverted? J Natl Cancer Inst 92: 92\u201393, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jnci\/92.1.48","volume":"92","author":"MD Radmacher","year":"2000","unstructured":"Radmacher MD, Simon R: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92: 48\u201353, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR50","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189\u20132197, 1999","journal-title":"JAMA"},{"key":"269875_CR51","unstructured":"Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A et al.: Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebocontrolled, randomized trials in postmenopausal women. Breast Cancer Res Treat 50: Abstract 2, 1998"},{"key":"269875_CR52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.1994.12.4.851","volume":"12","author":"SM Lippman","year":"1994","unstructured":"Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12: 851\u2013873, 1994","journal-title":"J Clin Oncol"},{"key":"269875_CR53","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1996.03530410063035","volume":"275","author":"J O'Shaughnessy","year":"1996","unstructured":"O'Shaughnessy J: Chemoprevention of breast cancer. JAMA 275: 1349\u20131353, 1996","journal-title":"JAMA"},{"key":"269875_CR54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jnci\/92.5.418","volume":"92","author":"RG Mehta","year":"2000","unstructured":"Mehta RG, Williamson E, Patel MK, Koefflex HP: A ligand of peroxisome proliferator-activated receptor \u03b3, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92: 418\u2013423, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR55","first-page":"2101","volume":"60","author":"RE Harris","year":"2000","unstructured":"Harris RE, Alshafie GA, Hussen A-I, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101\u20132103, 2000","journal-title":"Cancer Res"},{"key":"269875_CR56","first-page":"14","volume":"59","author":"JL Clifford","year":"1999","unstructured":"Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM: Retinoid receptor-dependent and-independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59: 14\u201318, 1999","journal-title":"Cancer Res"},{"key":"269875_CR57","first-page":"2493","volume":"59","author":"S-Y Sun","year":"1999","unstructured":"Sun S-Y, Li W, Yue P, Lippman SM, Hong WK, Lotan R: Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different machanisms. Cancer Res 59: 2493\u20132498, 1999","journal-title":"Cancer Res"},{"key":"269875_CR58","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/jnci\/91.21.1847","volume":"91","author":"U Veronesi","year":"1999","unstructured":"Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847\u20131856, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR59","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJM199505253322103","volume":"332","author":"R Lotan","year":"1995","unstructured":"Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ et al.: Suppression of retinoic acid receptor beta in oral premalignant lesions and its upregulation by isotretinoin. N Engl JMed 332: 1405\u20131410, 1995","journal-title":"N Engl JMed"},{"key":"269875_CR60","first-page":"4992","volume":"57","author":"XC Xu","year":"1997","unstructured":"Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F et al.: Progressive decrease in nuclear retinoic acid receptor b messenger RNA level during breast carcinogenesis. Cancer Res 57: 4992\u20134996, 1997","journal-title":"Cancer Res"},{"key":"269875_CR61","first-page":"4158","volume":"57","author":"M Widschwendter","year":"1997","unstructured":"Widschwendter M, Berger J, Daxenbichler G, Muller Holzner E, Widschwendter A, Mayr A et al.: Loss of retinoic acid receptor b expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue. Cancer Res 57: 4158\u20134161, 1997","journal-title":"Cancer Res"},{"key":"269875_CR62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/92.6.475","volume":"92","author":"YS Kuppumbatti","year":"2000","unstructured":"Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Wasman S, Mira-Y-Lopez R: Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst 92: 475\u2013480, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/jnci\/92.6.438","volume":"92","author":"MJ Spinella","year":"2000","unstructured":"Spinella MJ, Dmitrovsky E: Aberrant retinoid signaling and breast cancer: the view from outside the nucleus. J Natl Cancer Inst 92: 438\u2013440, 2000","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR64","first-page":"479","volume":"58","author":"ED Bischoff","year":"1998","unstructured":"Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) cause complete regression of mammary carcinoma. Cancer Res 58: 479\u2013484, 1998","journal-title":"Cancer Res"},{"key":"269875_CR65","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1093\/jnci\/91.24.2118","volume":"91","author":"ED Bischoff","year":"1999","unstructured":"Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD 1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91: 2118, 1999","journal-title":"J Natl Cancer Inst"},{"key":"269875_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0303-7207(96)03980-9","volume":"127","author":"SB Nunez","year":"1997","unstructured":"Nunez SB, Medin JA, Braissant O, Kemp L, Wahli W, Ozato K et al.: Retinoid X receptor and peroxisome proliferateractivated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol 127: 27\u201340, 1997","journal-title":"Mol Cell Endocrinol"},{"key":"269875_CR67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G","volume":"15","author":"TK Chen","year":"1996","unstructured":"Chen TK, Smith LM, Gebhardt D, Birrer MJ, Brown PH: Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog 15: 215\u2013226, 1996","journal-title":"Mol Carcinog"},{"key":"269875_CR68","first-page":"3046","volume":"57","author":"LM Smith","year":"1997","unstructured":"Smith LM, Birrer MJ, Stampher MR, Brown PH: Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res 57: 3046\u20133054, 1997","journal-title":"Cancer Res"},{"key":"269875_CR69","first-page":"4652","volume":"57","author":"LM Yang","year":"1997","unstructured":"Yang LM, Kim HT, Munoz-Medellin D, Reddy P, Brown PH: Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res 57: 4652\u20134661, 1997","journal-title":"Cancer Res"},{"key":"269875_CR70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1098-2744(199808)22:4<247::AID-MC6>3.0.CO;2-G","volume":"22","author":"W Yu","year":"1998","unstructured":"Yu W, Simmons-Menchaca M, You H, Brown PH, Birrer M, Sanders B, et al.: RRR-\u03b1-tocopheryl succinate induces prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog 22: 247\u2013257, 1998","journal-title":"Mol Carcinog"},{"key":"269875_CR71","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1038\/sj.onc.1202989","volume":"18","author":"LM Smith","year":"1999","unstructured":"Smith LM, Wise SC, Hendricks DT, Sabichi AL, Brown PH, Birer MJ: cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063\u20136070, 1999","journal-title":"Oncogene"},{"key":"269875_CR72","first-page":"251","volume":"5","author":"SR Johnston","year":"1999","unstructured":"Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M et al.: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251\u2013256, 1999","journal-title":"Clin Cancer Res"},{"key":"269875_CR73","unstructured":"Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG et al.: Tamoxifen-stimulated breast tumor growth in vivo is associated with oxidative stress and increased AP-1 activity. J Natl Cancer Inst (in press)"},{"key":"269875_CR74","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1006219411078","volume":"56","author":"L Yang","year":"1999","unstructured":"Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH: Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat 56: 277\u2013291, 1999","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006484604454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006484604454\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1006484604454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006484604454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:16:21Z","timestamp":1750479381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006484604454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["269875"],"URL":"https:\/\/doi.org\/10.1023\/a:1006484604454","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7]]}}}